Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease

NCT05670912 | Terminated Phase 2

• 1 other identifier: WLB-2022
• Study Type: interventional
• Target: 105
• Locations: 1 country
• Sites: 3

Brief Summary

In clinical trials of preclinical pharmacodynamic studies, Wei Li Bai capsules has been proved to significantly improve the learning and memory ability of Alzheimer's disease model. In this study, the researchers will use a multicenter, randomized, double-blind, placebo-controlled parallel method to recruit Alzheimer's disease patients to confirm the efficacy and safety of Wei Li Bai capsules. Confirmation of drug efficacy will be observed through changes in Alzheimer's disease patients' general cognitive function scores, scores of different cognitive domains, daily living activities, and symptom severities.

Conditions

Alzheimer Disease

Keywords

Alzheimer disease

Outcome Measures

Primary Outcomes (1)

• Alzheimer's Disease Assessment Scale-Cognitive section(ADAS-cog/11)

  Differences between the active group in changes in ADAS cog/11 scores (relative to baseline) at weeks 13 and 26 were compared with the placebo group. The ADAS-cog assesses cognitive function in seven components: word recall, instruction, structural practice, naming, conceptual practice, orientation, and word recognition. The total score ranges from 0 to 70, with lower scores representing milder disease.

  Change from baseline in ADAS-cog scores at Week 26.

Secondary Outcomes (4)

• Alzheimer's Disease Co-operative Study Activities of Daily Living (ADCS-ADL)

  Change from baseline in ADCS-ADL scores at Week 26.

• Clinician Interview Based Impression of Severity (CIBIC-plus)

  Change from baseline in CIBIC-plus scores at Week 26.

• Neuropsychiatric Inventory (NPI)

  Change from baseline in NPI's 12 behavioral domain scores at week 26.

• Neuropsychiatric Inventory (NPI)

  Change from baseline in Caregiver Stress Score on the NPI Scale at Week 26.

Study Arms (2)

active group

EXPERIMENTAL

Take 2 tablets each time (study drug), 3 times a day, a total of 0.9g per day. Take it with warm water half an hour before meals. Specifications: 0.15g/ pill (42mg sodium ferulate dihydrate, 42mg rhamnose monohydrate, 66mg chrysin)

Drug: Wei Li Bai capsules

control group

PLACEBO COMPARATOR

Take 2 tablets of the control drug (placebo) each time, 3 times a day, 0.9g a day. Take it with warm water half an hour before meals. Specification: 0.15g/ grain (microcrystalline cellulose)

Drug: Placebo Comparator of Wei Li Bai capsules

Interventions

Wei Li Bai capsules DRUG

The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.

active group

Placebo Comparator of Wei Li Bai capsules DRUG

The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.

control group

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 50 to 80 years old (including 50 and 80 years old), male or female;
• Meet the diagnostic criteria of "likely ad dementia" of the National Institute on aging Alzheimer's disease association (NIA-AA) (2011);
• The subjects are primary school graduates / graduates and above, and have the ability to complete the cognitive ability test and other tests specified in the program;
• Memory loss lasted for at least 6 months and tended to worsen gradually;
• Subjects with mild or moderate illness: 11 ≤ total score of MMSE ≤ 26;
• Total score of Clinical Dementia Rating Scale (CDR):
• Mild dementia: CDR = 1.0; Moderate dementia: CDR = 2.0;
• The total score of HIS ≤ 4;
• The total score of Hamilton Depression Scale (HAMD 17 item version) is ≤ 10;
• If the subject is currently receiving an approved AD treatment, such as acetylcholinesterase inhibitors (AChEI) and/or memantine, they must have been using a stable dose for at least 4 weeks prior to baseline and maintain a stable dose throughout the study;
• There was no obvious positive sign in nervous system examination;
• Coronal scanning of head MRI in screening stage: the MTA grade of medial temporal lobe atrophy visual assessment scale is grade 1-2. If the subject can provide the head MRI film that meets the requirements within 3 month before screening, it can be used as the basis for enrollment without repeated shooting; If the researcher cannot judge whether the subject's condition has changed, the coronal MRI scan of the head before enrollment can be added;
• The subjects should have stable and reliable caregivers, who will take care of them at least 3 days a week and at least 4 hours a day. The caregivers will accompany the subjects to participate in the whole process of the study. Caregivers must accompany the subjects to the study visit and assist the investigator in completing the Neuropsychiatric Inventory (NPI), Alzheimer's Disease Collaborative Study-Ability of Daily Living Scale (ADCS-ADL), and Clinician Interview Based Impression of Severity (CIBIC -plus), and other scale scores;
• Agree to participate and sign the informed consent form by the legal guardian. Due to the subject's limited cognitive ability and other reasons, the subject's signature is allowed to be left blank, and the reason is explained. In addition, the legal guardian shall sign the reason statement, and the legal guardian shall sign the informed consent.

You may not qualify if:

• During screening, MRI examination showed significant focal lesions, fulfilling one of the following conditions:
• ① There were more than 2 infarcts with diameter \> 2 cm at any site;
• ② MRI examination showed that there were infarcts with arbitrary diameter in key parts (such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, angular gyrus, cortex and other subcortical gray matter nuclei);
• ③ Fazekas scale grade of white matter lesions \>2;
• ④ There are other imaging evidences that do not support mild and moderate AD.
• Dementia caused by other reasons: vascular dementia, central nervous system infection, Creutzfeldt Jakob disease, Huntington's disease, Parkinson's disease, Lewy body dementia, traumatic dementia, other physical and chemical factors (such as drug poisoning, alcoholism, carbon monoxide poisoning, etc.), important physical diseases (such as hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space occupying lesions (such as subdural hematoma, brain tumor), endocrine disorders (such as thyroid disease, parathyroid disease), and vitamin B12, folic acid deficiency or any other known cause;
• Have suffered from central nervous system diseases (including stroke, optic neuromyelitis, epilepsy, etc.);
• Subjects who were diagnosed with psychiatric disorders according to DSM-V criteria, including schizophrenia or other mental diseases, bipolar disorder, severe depression or delirium;
• Abnormal laboratory indexes: liver function (ALT and AST) exceeded 1.5×ULN, renal function (CR) exceeded 1.5×ULN, and creatine kinase exceeded 2×ULN;
• Within 1 month of the screening visit, the subject has new or ongoing unstable or serious heart, lung, liver, kidney and hematopoietic diseases according to the judgment of the researcher, and does not meet the conditions for clinical research;
• Clinically, people with significant allergic reaction history, especially drug allergy history, or known allergy to this product and its excipients;
• Dyspepsia, esophageal reflux, gastric bleeding or peptic ulcer disease, frequent heartburn (≥ once a week) or any surgical operation that may affect drug absorption (such as partial / total gastrectomy, partial / total small bowel resection and cholecystectomy) within 6 months before screening;
• Alcohol or drug abusers;
• Human immunodeficiency virus antibody (ant HIV) and Treponema pallidum antibody (ant TP) are positive;
• Those who are currently using monoclonal antibody drugs for Alzheimer's disease (e.g., lecanemab, domanemab, etc.), psychotropic drugs, anti-Parkinson drugs, and opioid analgesics within 1 month before the visit;

Sponsors & Collaborators

• Capital Medical University: lead
• China-Japan Friendship Hospital: collaborator
• Beijing Friendship Hospital: collaborator

Study Sites (3)

China-Japan Friendship Hospital

Chaoyang, Beijing Municipality, China

Location

Beijing Friendship Hospital, Capital Medical University

Beijing, China

Location

Xuanwu Hospital of Capital Medical University

Beijing, China

Location

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director and Professor

Study Record Dates

• First Submitted: January 2, 2023
• First Posted: January 4, 2023
• Study Start: October 1, 2022
• Primary Completion: November 12, 2024
• Study Completion: November 12, 2024
• Last Updated: December 4, 2024

Record last verified: 2024-12

Locations

CN (3)